Eli Lilly deploys GLP-1 cash into psychedelics
The bull case presented for Eli Lilly: leveraging massive cash flow from obesity drugs to acquire early-stage, long-duration mental health platforms like psychedelic therapeutics.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.